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A B S T R A C T
Purpose
We have used a nonmyeloablative conditioning regimen consisting of total-body irradiation (2 Gy)
with or without fludarabine (30 mg/m2/d for 3 days) for related and unrelated hematopoietic cell
transplantation (HCT) in patients with hematologic malignancies who were not candidates for
conventional HCT because of age, medical comorbidities, or preceding high-dose HCT. This
approach relied on graft-versus-tumor (GVT) effects for control of malignancy.
Patients and Methods
We analyzed GVT effects in 322 patients given grafts from HLA-matched related (n  192)
or unrelated donors (n  130).
Results
Of the 221 patients with measurable disease at HCT, 126 (57%) achieved complete (n  98)
or partial (n  28) remissions. In multivariate analysis, there was a higher probability trend of
achieving complete remissions in patients with chronic extensive graft-versus-host disease
(GVHD; P  .07). One hundred eight patients (34%) relapsed or progressed. In multivariate
analysis, achievement of full donor chimerism was associated with a decreased risk of
relapse or progression (P  .002). Grade 2 to 4 acute GVHD had no significant impact on the
risk of relapse or progression but was associated with increased risk of nonrelapse mortality
and decreased probability of progression-free survival (PFS). Conversely, extensive chronic
GVHDwas associated with decreased risk of relapse or progression (P .006) and increased
probability of PFS (P  .003).
Conclusion
New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve
survival after allogeneic HCT after nonmyeloablative conditioning.
J Clin Oncol 23:1993-2003. © 2005 by American Society of Clinical Oncology
INTRODUCTION
It was recognized as early as 1956 that trans-
planted allogeneic immunocompetent cells
could eliminate leukemic cells in mice inde-
pendent of chemoradiotherapy.1 This was
termed a graft-versus-tumor (GVT) ef-
fect.2,3 Initial evidence for GVT effects in
humans came from studies reporting re-
duced leukemic relapse rates in allografted
patients who developed acute and/or
chronic graft-versus-host disease (GVHD)
compared with patients who did not.2,3
GVT effects were confirmed by other in-
vestigators who observed increased risks
of relapse in patients receiving T-cell– de-
pleted4 and syngeneic transplantations.5
Direct support for antitumor effects of al-
logeneic cells came from observations that
donor lymphocyte infusions (DLI) could
induce complete remissions in some pa-
tients with hematologic malignancies who
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No. % No. % No. %
Patient age, years
Median 54 54 54
Range 5-72 21-72 5-71
Recipient sex
Male 207 64 122 64 85 65
Female 115 35 70 36 45 35
Donor age, years
Median 46 52 34
Range 19-83 21-83 19-59
Donor sex
Male 167 52 90 47 77 59
Female 155 48 102 53 53 41
Female donor/male recipient 94 29 64 33 31 24
Diagnosis/status before allogeneic HCT
Acute myeloid leukemia
CR 1 15 4.7 11 5.7 4 3.1
CR  2 27 8.4 9 4.7 18 13.8
Not in CR 4 1.2 2 1.0 2 1.5
Acute lymphoblastic leukemia
CR 1 5 1.6 0 0.0 5 3.8
 CR 1 5 1.6 1 0.5 4 3.1
Chronic myeloid leukemia
CP 1 11 3.4 4 2.1 7 5.4
CP 2 3 0.9 1 0.5 2 1.5
 CP 4 1.2 2 1.0 2 1.5
Chronic lymphocytic leukemia
CR 1 0.3 0 0.0 1 0.8
PR 5 1.6 4 2.1 1 0.8
 PR 28 8.7 20 10.4 8 6.2
Myelodysplastic syndrome
RA/CR 32 10.0 17 8.9 15 11.5
 RA 13 4.0 8 4.2 5 3.8
Multiple myeloma
CR 6 1.9 6 3.1 0 0.0
MRD 16 5.0 15 7.8 1 0.8
PR 21 6.5 15 7.8 6 4.6
 PR 21 6.5 16 8.3 5 3.8
Non-Hodgkin’s lymphoma
CR 19 5.9 12 6.3 7 5.4
PR 19 5.9 15 7.8 4 3.1
 PR 30 9.3 16 8.3 14 10.8
Hodgkin’s disease
CR 1 0.3 0 0.0 1 0.8
PR 6 1.9 4 2.1 2 1.5
 PR 16 5.0 7 3.6 9 6.9
Myeloproliferative syndrome other than chronic myeloid leukemia 10 3.1 4 2.1 6 4.6
Waldenström’s macroglobulinemia 4 1.2 3 1.6 1 0.8
Disease risks†
Standard risk 153 47.5 101 52.6 52 40.0
High risk 144 44.7 77 40.1 67 51.5
Very high risk 25 7.8 14 7.3 11 8.5
Tumor chemosensitivity‡
Yes 110 — 82 — 28 —
No 80 — 49 — 31 —
Unknown 3 — 2 — 1 —
Measurable disease at HCT 221 68.6 143 74.5 78 60.0
(continued on following page)
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had relapsed after allogeneic hematopoietic cell trans-
plantation (HCT).6-8
The use of recently introduced reduced-intensity9-15
and truly nonmyeloablative conditioning regimens16-22
has shifted some or all of the burden of tumor-cell kill
from the conditioning regimens to the GVT effects.
These regimens are less toxic than conventional regimens
and allow for treatment of older patients and patients
with comorbid conditions.23,24
Here, we analyzed GVT effects in 322 patients with
various hematologic malignancies given grafts from HLA-
matched related or unrelated donors after a nonmyeloabla-
tive regimen consisting of total-body irradiation (TBI; 2
Gy) with or without fludarabine (30 mg/m2/d for 3 days)
and postgrafting immunosuppression with mycopheno-
late mofetil (MMF) and cyclosporine (CSP). This is the
first large series evaluating a relationship between acute




Table 1 lists the data from 322 consecutive patients with
hematologic malignancies administered allogeneic HCT after
nonmyeloablative conditioning at the Fred Hutchinson Cancer
Research Center, the University of Washington Medical Center,
the Children’s Hospital and Regional Medical Center, and the
Veterans Affairs Puget Sound Health Care System (all in Seattle,
WA) on prospective multicenter research protocols between










No. % No. % No. %
Conditioning regimen
TBI only 75 23.3 75 39.0 0 0
TBI  fludarabine 247 76.7 117 61.0 130 100
Tandem autologous-allogeneic HCT 59 18.3 54 28.1 5 3.8
Failed previous myeloablative HCT 87 27.0 36 18.8 51 39.2
Charlson comorbidity index
Score 0 151 46.9 92 47.9 59 45.4
Score 1-2 126 39.1 77 40.1 49 37.7
Score  2 29 9.0 11 5.7 18 13.8
Unknown 16 5.0 12 6.3 4 3.1
Donor
HLA-identical 296 91.9 187 97.4 109 83.8
1 antigen HLA mismatch 16 5.0 5 2.6 11 8.5
1 allele HLA mismatch 10 3.1 0 0 10 7.7
Stem-cell source
G-PBMC 308 95.7 192 100 116 89.2
Marrow 14 4.3 0 0 14 10.8
Cell dose,  106/kg recipient
CD34 cells
Median 7.8 9.4 6.5
Range 0.8-42.7 1.7-42.7 0.8-26.0
T cells
Median 304 346 248
Range 16-934 47-760 16-934
Follow-up for alive patients, months
Median 23 27 18
Range 3-72 3-72 3-49
Abbreviations: HCT, hematopoietic cell transplantation; CR, complete remission; PR, partial remission; CP, chronic phase; RA, refractory anemia; MRD,
minimal residual disease; TBI, total-body irradiation; G-PBMC, granulocyte colony-stimulating factor–mobilized peripheral-blood mononuclear cells; RAEB,
refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; AML, acute myeloid leukemia.
Including patients who received chemotherapy for RAEB, RAEBT, or AML now either in CR or in RA.
†Standard risks were defined as acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission,
myelodysplastic syndrome-refractory anemia, chronic myeloid leukemia in first chronic phase, chronic lymphocytic leukemia, low-grade non-Hodgkin’s
lymphoma, high- or intermediate-grade non-Hodgkin’s lymphoma in complete remission, Hodgkin’s disease in complete remission, and multiple myeloma in
complete remission or with minimal residual disease; very high risks were defined as acute leukemia above second complete remission, chronic myeloid
leukemia in accelerated phase or blast crisis and myelodysplastic syndrome-refractory anemia with blast excess or above; all other diagnoses were classified
as high risk.
‡Restricted to patients with chronic lymphocytic leukemia, lymphomas, multiple myeloma, and Waldenström’s disease.
GVT Effects After Nonmyeloablative HCT
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November 1998 and December 2003. Here, we analyzed the data
retrospectively for GVT effects as of March 31, 2004. To assure
consistent grading and treatment of acute and chronic GVHD,
only patients treated in Seattle were included in this analysis.
Patients were considered ineligible for conventional allogeneic
HCT because of age and/or comorbidities or preceding high-dose
HCT.17,20,25 For patients in good medical condition with chronic
myeloid leukemia (CML) in first chronic phase, myelodysplastic
syndrome (MDS), and acute myeloid leukemia (AML) in first
complete remission, the age cutoff was 65 years with sibling grafts
and 50 years with unrelated grafts. For patients in good medical
condition with B-cell malignancies, the age cutoff was 50 years
regardless of stem-cell source. Patients who had experienced fail-
ure with high-dose HCT and patients with comorbid conditions
underwent nonmyeloablative HCT, even if they were younger
than the age cutoffs. Characteristics of the patients are listed in
Table 1. Median follow-up after HCT was 23 months (range, 3 to
72 months).
Median patient age was 54 years (range, 5 to 72 years). Sixty
percent of patients received grafts from related donors, and 40%
received grafts from unrelated donors. Stem-cell sources were
granulocyte colony-stimulating factor–mobilized peripheral-
blood mononuclear cells (G-PBMC) in 308 patients and marrow
in 14 patients; the latter patients were all recipients of unrelated
grafts. Patients were classified as being at standard risk, high risk,
or very high risk of progression, as described in Table 1.
Compatibility between patients and donors for HLA-A, -B,
and -C antigens was assessed by intermediate-resolution DNA
typing to a level at least as sensitive as serology, and compati-
bility between patients and donors for HLA-DRB1 and HLA-
DQB1 was assessed by high-resolution techniques.26 Two
hundred ninety-six patients received grafts fromHLA-matched
donors, 16 grafts were from donors mismatched for a single
class I HLA antigen (seven of these donors also had one addi-
tional mismatch at the allele level), and 10 grafts were from
donors mismatched for one HLA class I allele.
Pretransplantation comorbidities were determined from the
patients’ pretransplantation evaluation notes and scored using a
template adapted from the Charlson comorbidity index,27 as pre-
viously reported.23,24 Prospective research protocols and the cur-
rent retrospective studywere approved by the Institutional Review




Seventy-five recipients of HLA-matched related grafts were
conditioned with 2 Gy of TBI alone,17 whereas the remaining 247
related and unrelated recipients were administered 2 Gy of TBI on
day 0 and fludarabine 30mg/m2/d on days4,3, and2 before
HCT.17,20,21 Postgrafting immunosuppression includedMMF (15
mg/kg orally twice a day from the evening of day 0 until day27
for related recipients or until day 40 at full dose and then tapered
through day 96 for unrelated recipients) and CSP (6.25 mg/kg
orally twice a day from day 3 to days 35 or 56 for related
recipients or to day 100 for unrelated recipients). Seventy-nine
unrelated recipients receivedMMF 15mg/kg three times a day. In
the absence of GVHD, CSP was tapered through days 56, 77, or
180 for related recipients and day 180 for unrelated recipients.
GVHD Grading and Therapy and Supportive Care
Diagnosis and clinical grading of GVHD were performed
according to established criteria.28 Treatment was given for grade
2 to 4 acute GVHD and for extensive chronic GVHD.29 Initial
Fig 1. Cumulative incidence of achieving full donor T-cell chimerism.




Failure of Progression-Free Survival (178 events)
HR 95% CI P
Disease risk
Standard 153 1.0 —
High 144 1.7 1.2 to 2.3
Very high 25 3.2 2.0 to 5.2  .0001
Charlson comorbidity score
0-2 293 1.0 —
3 29 3.6 2.3 to 5.5  .0001
Tandem autologous and allogeneic HCT
No 263 1.0 —
Yes 59 0.5 0.3 to 0.8 .0008
Abbreviations: HCT, hematopoietic cell transplantation; HR, hazard ratio.
Factors significant at 0.05 level in stepwise selection procedure. Other variables considered were prior HCT failure, disease sensitivity for B-cell malignancy,
CD3 cell dose, CD34 cell dose.
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treatment usually consisted of prednisolone 1 to 2 mg/kg/d, with
taper initiated within 14 days. In addition, CSP was usually re-
sumed at full doses. Steroid-refractory acute GVHDwas treated as
per available investigational protocols or other salvage regimens.
Treatment of chronic GVHD consisted of prednisolone (1mg/kg)
with or without alternate-day CSP.30
Standard prophylaxis against infections was used.31 Patients
with chronic GVHD requiring systemic immunosuppressive ther-
apy continued prophylaxis against Pneumocystis carinii and pneu-
mococcal infections.
Follow-Up
Patients were examined by a healthcare provider at least three
times a week for the first month and then weekly or more fre-
quently, depending on the patient’s clinical status. Disease-
dependent restaging evaluations after HCT occurred monthly for
the first 3 months and then at 6 months, 1 year, and yearly there-
after. For chimerism analyses, T cells were isolated from the pe-
ripheral blood on days 28, 56, 84, 180, and 365, and then yearly
after HCT. Percentages of donor-host chimerism were evaluated
by fluorescent in situ hybridization for X and Y chromosomes if
patients and donors were sex mismatched or by polymerase chain
reaction–based amplification of variable-number tandem repeat
sequences unique to donors and hosts if patients and donors were
sex matched.32
Treatment of Persistent, Progressive, or Relapsed
Diseases and Prevention of Graft Rejection
Persistent, progressive, or relapsed malignancies in the ab-
sence of severe manifestations of acute and chronic GVHD were
treated by rapid taper and discontinuation of systemic immuno-
suppression to initiate GVT effects. In addition, 27 patients re-
ceivedDLI33 for disease relapse or progression (n 14), persistent
disease (n 5), poor T-cell chimerism with or without persistent
disease (n  7), and Epstein-Barr virus-lymphoproliferative dis-
ease in donor cells (n 1).
Statistical Methods
Survival and progression-free survival (PFS) were estimated
by the Kaplan-Meier method. Cumulative incidence estimates
were calculated using methods previously described.34 Hazard
ratios (HRs)were estimated fromCox regressionmodels. Progres-
sion and nonrelapsemortality were treated asmutually competing
events in the analysis of each other; death was a competing event
for achieving complete remission. Patients with relapse or pro-
gression who subsequently responded to DLI or discontinuation
of postgrafting immunosuppression were listed as relapsed,
whereas the 13 patients who received DLI before or without expe-
riencing progression or relapse were carried forward. For pre-
transplantation risk factors, multivariatemodels were constructed
in a stepwise fashion using a threshold significance level of 0.05 for
inclusion in the model. These pretransplantation factors were
included in multivariate analysis of GVT effects.
Putative GVT effects were evaluated using time-dependent
Cox regression models. To accommodate changes in GVHD with
time after transplantation, patients were assigned to four time-
dependent acute GVHD comparison groups (no acute GVHD,
grade 1, grade 2, and grade 3 to 4) and to two time-dependent
chronic GVHD groups (no or limited chronic GVHD and clinical
extensive chronic GVHD). All patients were considered to be in
the no acute GVHD and no chronic GVHD groups on day 0. They
were then assigned to their acute GVHD group and/or their
chronic GVHD group at the time of onset of each grade of acute
or chronic extensive GVHD, respectively, and their subsequent
probabilities of achieving complete remissions, PFS, nonre-
lapse mortality, and progression or relapse were compared with
patients surviving a similar length of time without developing
acute or chronic extensive GVHD. Graft rejection was also
treated as a time-dependent covariate. Patients who experi-
enced graft rejection were similarly assigned to a group named
rejection and were compared with patients surviving a similar
length of time without experiencing graft rejection. To avoid
confusing the effects of rejection on impact of GVHD on GVT
effects, any indicator of GVHD was dismissed at the time of
graft rejection. Achievement of full (defined as  95%) donor
T-cell chimerism was also similarly treated as a time-dependent
covariate. Multivariate P values for a variable were based on
adjustment for all other variables in the model. All P values
were two-sided.
Tests for a differential effect of GVHD on outcome as a
function of donor status or disease risk were conducted by adding
interaction terms for the time-dependent indicators of grade 2
GVHD, grade 3 GVHD, and chronic extensive GVHD. Models
with and without the interaction terms were compared by likeli-
hood ratio test.
To illustrate the effects of GVHD on subsequent events, we
constructed semi-landmark plots of the cumulative incidence of
progression and nonrelapse mortality. For patients with a diagno-
sis of acute or chronic GVHD, cumulative incidence of these
events was plotted as a function of time since onset of each grade of
acute GVHD and onset of extensive chronic GVHD. A landmark
comparison group comprised patients who were disease free and
without a diagnosis of acute GVHD at day 40 or extensive chronic
GVHD at day 135; these were the median days of onset for acute
and extensive chronic GVHD, respectively. Cumulative incidence
for these groups was plotted as a function of time since the land-
mark day. For patients with grades 0, 1, or 2 acute GVHD or
without extensive chronicGHVD, the incidenceswere conditional
on remaining in the same GVHD state (ie, not having moved to a
different grade or diagnosis).
RESULTS
Outcomes After HCT
Twenty-one patients rejected their grafts, whereas 301
patients had durable donor engraftment as assessed by ge-
netic markers. The cumulative incidence of achieving full
donor ( 95%) T-cell chimerism is shown in Figure 1.
Grades 1, 2, 3 and 4 acute GVHDwere seen in 8.1%, 43.8%,
10.6%, and 3.4%of patients, respectively. Extensive chronic
GVHDwas seen in 56.2% of patients, and of these patients,
19.9% had de novo35 extensive chronic GVHD. The 3-year
probability of overall survival was 49.7%. The 3-year prob-
ability of PFS was 38.5% (48.6%, 34.2%, and 5.9%, respec-
tively, for patients with standard-, high-, and very high–risk
disease). Inmultivariate analysis, factors significantly influ-
encing PFS included disease risk (P  .0001), Charlson
comorbidity score (P .0001), and tandem autologous and
allogeneic HCT (P .0008; Table 2).
GVT Effects After Nonmyeloablative HCT
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Disease Responses in Patients With Measurable
Disease at HCT
Two hundred twenty-one of the 322 patients hadmea-
surable malignant disease before transplantation. Ninety-
eight (44%) of these patients achieved complete remissions
27 to 963 days (median, 176 days) after HCT (Fig 2), and 28
(13%) were in partial remission at the time of analysis.
Multivariate time-dependent analysis identified chemosen-
sitivity for B-cell malignancies (HR, 2.0; 95% CI, 1.2 to 3.2;
P .02) and tandem autologous and allogeneic HCT (HR,
0.6; 95% CI, 0.3 to 1.0; P  .04) as pretransplantation
factors associated with probabilities of achieving complete
remissions after HCT. After excluding patients who re-
ceived tandemHCT, 76 (45%) of 170 patients withmeasur-
able disease at HCT achieved complete remission 27 to 963
days (median, 144 days) after HCT.
Impact of GVHD and Graft Rejection on
Probability of Achieving Complete Remissions
Multivariate analysis demonstrated that acute GVHD
of any grade was not associated with an increased probabil-
ity of achieving a complete remission (Table 3). There was a
trend for a higher probability of achieving complete remis-
sions in patients with extensive chronic GVHD (P  .07),
suggesting a GVT effect associated with extensive chronic
GVHD. However, limited chronic GVHD was not associ-
ated with achievement of complete remissions (HR, 1.2;
95% CI, 0.3 to 4.1; P  .82). There was no significant
differential effect of GVHD on probability of achieving
complete remissions as a function of donor status (P .22).
Comparable results were obtained when tandem autolo-
gous and allogeneic HCT recipients were excluded from the
analysis (Table 3).
Impact of GVHD and Donor T-Cell Chimerism on
Relapse and Progression Risk (Figs 2A and 3A)
In multivariate analysis, extensive chronic GVHD was
associated with a decreased risk of progression or relapse
(P  .006; Table 4). Patients with grade 1 acute GVHD
tended to have less progression or relapse (P  .07). Con-
versely, grade 2 to 4 acute GVHDdid not significantly affect
the risk of progression or relapse (Table 4); limited chronic
GVHD also did not significantly affect the risk of progres-
sion or relapse (HR, 0.8; 95% CI, 0.3 to 2.1; P  .71). No
Fig 2. Cumulative incidence of achieving a complete remission in patients
with measurable disease at transplantation. MDS, myelodysplastic syn-
drome; MPD, myeloproliferative disease; CML, chronic myeloid leukemia;
AML, acute myeloid leukemia.
Table 3. Effect of Acute and Chronic GVHD, and Graft Rejection on Probabilities to Achieve Complete Remissions in Patients With Measurable
Disease at Transplantation
Factor
All Patients (N  221)
All Patients Except for Tandem Autologous and
Allogeneic HCT (n  170)
No. of
Patients
Complete Remissions (98 events)
No. of
Patients
Complete Remissions (76 events)
HR 95% CI P HR† 95% CI P
Acute GVHD‡
No 82 1.0 — 64 1.0 —
Grade 1 17 0.7 0.3 to 1.7 .47 10 0.6 0.2 to 1.9 .34
Grade 2 96 1.1 0.7 to 1.7 .72 75 1.4 0.8 to 2.4 .22
Grade 3/4 26 1.2 0.6 to 2.5 .61 21 1.7 0.8 to 3.6 .18
Chronic GVHD,‡ extensive
No 128 1.0 — 106 1.0 —
Yes 93 1.7 1.0 to 3.2 .07 64 2.0 1.0 to 4.0 .07
Graft rejection§
No 207 1.0 — 156 1.0 —
Yes 14 0.3 0.1 to 1.5 .14 14 0.4 0.1 to 1.9 .27
Abbreviations: GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HR, hazard ratio; CR, complete remission.
Adjusted for disease sensitivity for B-cell malignancies and tandem autologous and allogeneic HCT.
†Adjusted for disease sensitivity for B-cell malignancies. GVHD and graft rejection were analyzed as a time-dependent risk factors.
‡Number of patients at risk, excluding seven and six patients with acute GVHD and 29 and 26 patients with chronic GVHD occurring after complete
remission for all patients and all patients except those who underwent tandem HCT, respectively.
§Number of patients at risk, excluding rejection occurring after CR (one patient).
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significant differential effect of acute and chronicGVHDon
relapse or progression risk as a function of donor status
(P .64) or disease group (P .35) was seen. Achievement
of full donor T-cell chimerism was strongly correlated with
decreased risk of progression or relapse (P  .002). When
separately evaluating specific disease groups, the strongest
beneficial effect of extensive chronic GVHD was observed
in patients with AML, MDS, and myeloproliferative disor-
ders (excluding CML; P  .0009; Table 5). Similar trends
were observed for patients with lymphoma and chronic
lymphocytic leukemia (P  .12), but the number of CML
patients was too small to assess the impact of GVHD on
disease relapse or progression.
Impact of Acute GVHD and Donor T-Cell
Chimerism on Nonrelapse Mortality and PFS
(Figs 3B and 3C and 4)
In multivariate analysis, grade 1 acute GVHD reduced
the risk of nonrelapse mortality (P .03), but the number
of patients in this group was quite small (Table 4). Grade 2
(P  .04) and grade 3 to 4 (P  .0001) acute GVHD
increased nonrelapse mortality. Interestingly, extensive
chronic GVHDwas not associated with an increased risk of
nonrelapse mortality. There was no significant differential
effect of acute and chronic GVHD on nonrelapse mortality
as a function of donor status (P .99).
In multivariate analysis, grade 1 acute GVHD was as-
sociated with significantly better PFS (P  .02), whereas
grade 3 to 4 acute GVHD (P  .0001) was associated with
decreased PFS (Table 4). Extensive chronic GVHD was
associated with improved PFS (P  .003). The beneficial
effects of extensive chronic GVHD on PFS were observed
both in patients who had preceding grade 2 to 4 acute
GVHD (HR, 0.5; 95% CI, 0.3 to 0.8; P  .009) and in
patients with de novo35 extensive chronic GVHD (HR, 0.5;
95% CI, 0.2 to 1.0; P  .04). These associations persisted
when results were analyzed separately in patients with
standard-risk disease (HR, 0.4; 95% CI, 0.2 to 0.8; P .01)
and high- or very high–risk disease (HR, 0.5; 95%CI, 0.3 to
0.9; P  .02). No significant differential effects of acute
and chronic GVHD on PFS as a function of donor status
(P .57) or disease risk (P .58) were seen.
DISCUSSION
Disease responses after allogeneic HCT with nonmyeloabla-
tive conditioning are largely attributed to immunologically
mediatedGVT effects. The biology of these responses remains
poorly defined but has been thought to involve reactions to
polymorphic minor histocompatibility antigens expressed ei-
ther specifically on hematopoietic cells or more widely on a
number of tissue cells.36 This study sought to define GVT
responses after a mild conditioning regimen of 2 Gy of TBI
with or without added fludarabine and to evaluate their rela-
tionshipwith donorT-cell engraftment and acute and chronic
GVHD.2,5 Given the risk of GVHD-associated mortality, we
also investigated how those parameters affected PFS.
Historically, analyses of associations between GVHD
and disease progression or relapse have posed several meth-
odologic problems. For example, some studies did not con-
sider patients who died or relapsed too early to develop
acute or chronic GVHD and, therefore, might have overes-
timated the positive impacts of mild acute GVHD and of
Fig 3. Semi-landmark plots illustrating impact of acute graft-versus-host
disease on post-hematopoietic cell transplantation outcomes.
GVT Effects After Nonmyeloablative HCT
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chronicGVHD.37,38 Other studies compared the incidences
of relapse and PFS from a specific landmark time.39,40How-
ever, landmark analyses are not ideal because patients who
relapsed or did not survive to landmark cutoff were ex-
cluded from the analyses. In this study, we chose time-
dependent logistical regression analyses, whichwere similar
to those reported by others,5 that included data from all
patients to avoid bias from selection timepoints or fromnot
considering patients who died or relapsed early.
Fifty-seven percent of patients withmeasurable disease
at HCT responded. The delayed time to achieve complete
remissions (median, 176 days) and the fact that none of the
patients with graft rejection achieved sustained complete
remissions were consistent with the notion that responses
Table 4. Effect of Acute and Chronic GVHD and Graft Rejection on the Risks of Failure of PFS, Nonrelapse Mortality, or Progression or
Relapse in 322 Patients
Factor
Failure of PFS (178 events)
Progression or Relapse
(108 events) Nonrelapse Mortality (70 events)
HR† 95% CI P HR† 95% CI P HR† 95% CI P
Acute GVHD‡
No, n  122 1.0 — 1.0 — 1.0 —
Grade 1, n  22 0.3 0.1 to 0.8 .02 0.3 0.1 to 1.1 .07 0.0 — .03
Grade 2, n  136 1.3 0.9 to 1.8 .22 1.0 0.7 to 1.6 .91 2.0 1.0 to 4.0 .04
Grade 3/4, n  42 2.8 1.8 to 4.4  .0001 0.7 0.3 to 1.7 .44 9.5 4.7 to 19  .0001
Chronic GVHD§
(clinical extensive)
No, n  168 1.0 — 1.0 — 1.0 —
Yes, n  154 0.5 0.3 to 0.8 .003 0.4 0.2 to 0.8 .006 0.6 0.3 to 1.1 .12
Rejection
No, n  309 1.0 — 1.0 — 1.0 —
Yes, n  13 1.6 0.8 to 3.4 .21 2.0 0.9 to 4.4 .10 0.7 0.1 to 5.5 .73
Achievement of full donor
( 95%) T-cell chimerism
No, n  78 1.0 — 1.0 — 1.0 —
Yes, n  244 0.8 0.5 to 1.1 .11 0.5 0.3 to 0.8 .002 1.5 0.8 to 2.8 .15
Abbreviations: GVHD, graft-versus-host disease; PFS, progression-free survival; HR, hazard ratio; HCT, hematopoietic cell transplantation.
Fifty-three of these 70 patients with events had preceding grade 2 to 4 acute GVHD. The median time between GVHD onset and death was 110 days (range,
3 to 1,096 days). Causes of nonrelapse deaths in the 70 patients were infections with or without GVHD (n  42), GVHD without infections (n 10), idiopathic
pneumonitis (n  4), concurrent nonhematologic cancer (n  3), or others (n  11).
†Effects of GVHD, graft rejection, and achievement of full donor T-cell chimerism were evaluated using time-dependent Cox regression models. Multivariate
P values for a variable were based on adjustment for tandem autologous and allogeneic HCT, Charlson comorbidity index score at HCT (0 to 2, 3), and
disease risk (low, high, very high) in the model. All P values were two-sided.
‡Excluded acute GVHD occurring after relapse (13 patients).
§Excluded chronic GVHD occurring after relapse (24 patients).
Excluded rejections occurring after relapse (eight patients).
Table 5. Effect of Acute and Chronic GVHD on the Risks of Progression or Relapse by Disease Group
Factor
Multiple Myeloma
(n  64, 17 events)
Lymphoma and CLL
(n  129, 38 events)
AML, MDS, and MPD
(n  101, 37 events)
CML
(n  18, 10 events)
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Acute GVHD
No 1.0 —
Grade 1 0.3 0.1 to 1.1 .07
Grade 2 1.2 0.5 to 3.0 .64 0.7 0.4 to 1.5 .39 1.3 0.7 to 2.4 .37 0.6 0.2 to 2.5 .52
Grade 3 0.6 0.1 to 5.3 .67 0.4 0.1 to 1.9 .26 1.2 0.3 to 5.1 .81 2.3 0.3 to 17 .42
Chronic GVHD
No 1.0 —
Yes 0.7 0.2 to 1.8 .41 0.5 0.2 to 1.2 .12 0.2 0.1 to 0.5 .0009 1.2 0.2 to 7.4 .88
Abbreviations: GVHD, graft-versus-host disease; CLL, chronic lymphocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPD,
myeloproliferative disease; CML, chronic myeloid leukemia; HR, hazard ratio; HCT, hematopoietic cell transplantation.
Effects of GVHD were evaluated using time-dependent Cox regression models. Multivariate P values for a variable were based on adjustment for tandem
autologous and allogeneic HCT, Charlson comorbidity index score at HCT (0 to 2, 3), and disease risk (low, high, very high) in the model. All P values were
two-sided.
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were a result of GVT effects. The persistence of host
antigen-presenting cells, including dendritic cells, during
the first months after HCT with nonmyeloablative condi-
tioning might, in part, be responsible for efficient donor
T-cell immunization against host hematopoietic cells re-
sulting in GVT effects.41 Strong antitumor responses were
seen in some patients in the absence of clinical GVHD,
suggesting that those responses were directed against anti-
gens preferentially expressed on hematopoietic cells.36
Achievement of full donor T-cell chimerism was strongly
associated with reduced risk of progression or relapse,
which is possibly an expression of alloreactivity against both
normal host hematopoiesis and tumor cells.However, there
was also a suggestion that full donor chimerism increased
nonrelapse mortality. The latter observationmay be related
to the apparent strong association between high levels of
donor T-cell chimerism early after HCT and increased risk
of grade 2 to 4 acute GVHD.22
Surprisingly, acute GVHD was not associated with an
increased probability of achieving complete remissions in
the current study. One explanation might be that cortico-
steroids and other immunosuppressive agents used to treat
acute GVHD blunted GVT effects. Additionally, potential
antitumor benefits of acute GVHD might have been offset
by early GVHD-related mortality.
Accordingly, PFS of patients with grade 3 to 4 acute
GVHDwas significantly worse than the PFS of patients with
grade 0 to 1 acute GVHD, and even patients with grade 2
acute GVHD showed a strong trend for worse PFS. Nonre-
lapse deaths occurred a median of 110 days after GVHD
onset and were mainly a result of infections.42 A number of
previous studies have analyzed the impact of acute GVHD
in patients who underwent allogeneic HCT after myeloab-
lative conditioning. Weiden et al2 first showed comparable
survivals of leukemic patients with or without GVHD be-
cause the lessened probability of recurrent leukemia in pa-
tients with GVHD was offset by a greater probability of
nonrelapse death. Significantly lower survivals were seen in
patients with aplastic anemia and with various hematologic
malignancies who had grade 2 to 4 acute GVHD compared
with patients with grade 1 or no GVHD.43,44 Sullivan et al39
showed adverse effects of acute GVHD on survival in pa-
tients with AML in first complete remission and in patients
with CML in first chronic phase but showed improved
survival in patients receiving HCT for more advanced dis-
eases. Kanda et al40 reported significantly impaired PFS in
patients with grade 2 to 4 acute GVHD. A benefit of mild
grade 1 acute GVHD was only seen in high-risk patients.
Recently, Neudorf et al45 reported beneficial effects of grade
1 to 2 acute GVHD but detrimental effects of grade 3 to 4
acute GVHD in children with AML. Current results suggest
that optimizing postgrafting immunosuppression to avoid
acute GVHD requiring high-dose corticosteroids might re-
duce nonrelapse mortality without impairing GVT effects
after nonmyeloablative conditioning.
In contrast to acute GVHD, patients with extensive
chronic GVHD experienced significantly less disease pro-
gression, no increase in nonrelapse mortality, and, accord-
ingly, improved PFS when compared with patients without
extensive chronic GVHD. The beneficial effects of extensive
chronic GVHD were the strongest for patients with AML
andMDS, but similar trends were also observed for patients
with lymphoma and chronic lymphocytic leukemia. The
Fig 4. Semi-landmark plots illustrating impact of chronic extensive graft-
versus-host disease on post-hematopoietic cell transplantation outcomes.
Clin Ext, clinical extensive.
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lack of an association between chronic GVHD and nonre-
lapsemortality, although surprising, was unlikely a result of
insufficient follow-up because the median follow-up after
extensive chronic GVHD onset was 12 months (range, 0 to
62 months) and was more than 2 and 3 years for 57 and 25
patients, respectively. We have previously reported that
nonmyeloablative recipients with chronic GVHD were
more likely to discontinue immunosuppressive therapy and
less likely to die fromGVHD thanmyeloablative recipients,
which may partly explain the low nonrelapse mortality
caused by chronic GVHD in our study.29 Previous reports
in patients who underwent allogeneic grafts after myeloab-
lative conditioning have also shown beneficial effects of
chronic GVHD on relapse3,5,38,39 and PFS.3,38
Although acute GVHD has been identified as a major
risk factor for subsequent development of chronic
GVHD,46,47 several studies have shown that certain thera-
peutic interventions either reduced the risk of acute GVHD
without changing the incidence of chronic GVHD or did
not affect the level of acute GVHD while increasing the
frequency of chronic GVHD. For example, in recipients of
HLA-identical sibling grafts, the use of G-PBMC instead of
marrow,48-50 the addition of PBMC to marrow,51 and high
CD34 cell content in the G-PBMC product52 did not
change the risk of acute GVHD, but all three interventions
increased the frequency of chronic GVHD. In both related
and unrelated graft recipients, substituting the combina-
tion of tacrolimus plus methotrexate for CSP plus metho-
trexate reduced the incidence of acute GVHD but did not
change the incidence of chronic GVHD.53,54 Similar find-
ings weremade previously in two randomized studies com-
paring methotrexate plus CSP to either drug alone.55,56
New approaches aimed at reducing the incidence of grade 2
to 4 acute GVHD might improve PFS of allogeneic recipi-
ents after nonmyeloablative conditioning.
■ ■ ■
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